Dear colleagues -
Please find attached the weekly vaccine marketplace update as of 18 March. Some highlights:
- AstraZeneca and the EU: Germany, France, Italy and Spain said they would resume using the Oxford/AstraZeneca coronavirus vaccine after the EU drugs regulator EMA and the WHO said there was a “clear scientific conclusion” that the jab was “safe and effective”. This was after 13 EU countries suspended use of the vaccine amid concerns over blood clots.
- Vaccine diplomacy: The United States, India, Australia and Japan have pledged to deliver a billion doses of Covid-19 vaccine throughout the Indo-Pacific by the end of 2022 in what is widely seen as a bid to counter China's influence in the region. While in separate move, China is donating 300,000 doses of COVID-19 vaccines to U.N. peacekeepers, with priority given to those serving in Africa.
- Johnson & Johnson gets two major approvals: The European Commission granted a conditional marketing authorization after the EU’s drugs regulator recommended approval for all adults earlier Thursday. It’s the fourth shot to be cleared in the region. Shortly thereafter, the World Health Organization granted an emergency use listing for the coronavirus vaccine made by Johnson & Johnson, meaning the one-dose shot can now theoretically be used as part of the international COVAX effort.
In terms of vaccinations, more than 400 million doses (Last week: 330 million) have been administered across 132 countries (Last week: 121 countries), according to data collected by Bloomberg.
The latest rate was roughly 9.64 million doses a day (Last week: 8.47 million doses a day).
Thank you and kind regards,
Sebastian
Sebastian Molineus
Regional Director for the South Caucasus
Europe and Central Asia
T +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
Regional Director for the South Caucasus
Europe and Central AsiaT +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
@smolineus
  |
_____________________________________________
From: Sebastian-A Molineus
Sent: Friday, March 12, 2021 8:15 AM
To: Ekaterine Tikaradze; Tamar Gabunia ; Ivane Matchavariani (i.matchavariani@mof.ge)
Cc: Tania Dmytraczenko; Ahmet Levent Yener ; Volkan Cetinkaya ; Nino V. Moroshkina
Subject: RE: Weekly Vaccine Marketplace Update as of 11 March, 2021 - with attachment
From: Sebastian-A Molineus
Sent: Friday, March 12, 2021 8:15 AM
To: Ekaterine Tikaradze
Cc: Tania Dmytraczenko
Subject: RE: Weekly Vaccine Marketplace Update as of 11 March, 2021 - with attachment
Dear Tamar – it was a pleasure meeting last night to help answer some of your questions on vaccine purchasing strategy. As discussed, we are putting you in touch with the authorities in Ukraine
(for their experience with Crown), as well as the UAE (re. Sinopharm), and Armenia (to discuss possibly pooling, e.g. with respect to NOVOVAX, where I’d like to again highlight our advice to strike early, fast, and at great bulk!). On NOVOVAX, please note
that they just released their updated results last night (see https://ir.novavax.com/node/15656/pdf), and they are: 96.4% effective against mild disease; 100% effective
against hospitalizations; and 100% effective against death. Again, you may wish to move quickly on this and purchase larger quantities given the first mover advantage we discussed last night!
And attached is this week’s vaccine marketplace update – shared with you on a confidential basis. Of note is that Italy approved the AstraZeneca vaccine for over-65s, following a number of other
European nations reversing their previous decisions to not use the vaccine for people over-65, including France and Germany.
<< File: Vaccine Marketplace Update - as at 03-11-21.pptx >>
Thank you and kind regards,
Sebastian
Sebastian Molineus
Regional Director for the South Caucasus
Europe and Central Asia
T +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
Regional Director for the South Caucasus
Europe and Central AsiaT +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
@smolineus |
_____________________________________________
From: Sebastian-A Molineus
Sent: Sunday, March 7, 2021 2:27 PM
To: Ivane Matchavariani (i.matchavariani@mof.ge); Ekaterine Tikaradze ; Tamar Gabunia
Cc: Tania Dmytraczenko; Ahmet Levent Yener ; Volkan Cetinkaya ; Nino V. Moroshkina
Subject: Weekly Vaccine Marketplace Update as of 4 March, 2021 - with attachment
From: Sebastian-A Molineus
Sent: Sunday, March 7, 2021 2:27 PM
To: Ivane Matchavariani (i.matchavariani@mof.ge)
Cc: Tania Dmytraczenko
Subject: Weekly Vaccine Marketplace Update as of 4 March, 2021 - with attachment
<< File: Vaccine Marketplace Update - as at 03-04-21.pptx >>
Dear Ivane, Eka, and Tamar -
please find attached the weekly vaccine marketplace update. A few highlights:
- Johnson and Johnson was approved by the FDA. This is the first single dose vaccine to be approved by an SRA. It is considered a game changer within the USA because it is the first non-mRNA vaccine which means it can be stored and transported at normal freezer temperatures.
- COVAX is starting to gain steam. Ghana, Ivory Coast, South Korea, India and Colombia have already received their first deliveries of vaccines through Covax. Nigeria, Angola, Cambodia all received their first vaccine doses via Covax this week, with the DR Congo also scheduled for a delivery. And this of course now also includes Georgia!
- The EU is considering switching to Emergency Use approvals. Under pressure to speed up its approval process, The European Commission said that it was considering emergency approvals for COVID-19 vaccines as a faster alternative to more rigorous conditional marketing authorizations which have been used so far.
In terms of Vaccinations; more than 271 million doses (Last week: 218 million) have been administered across 108 countries (Last week: 99 countries), according to data collected
by Bloomberg. The latest rate was roughly 6.36 million doses a day (Last week: 6.14 million doses a day).
As always, I would ask that you pls. keep this information confidential.
Thank you and kind regards,
Sebastian
Sebastian Molineus
Regional Director for the South Caucasus
Europe and Central Asia
T +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
Regional Director for the South Caucasus
Europe and Central AsiaT +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca
@smolineus |